Study: Remdesivir significantly reduces COVID-19 hospitalizations
The antiviral drug was tested on over 500 patients considered high risk due to either their health conditions or age.
News 12 Staff
•
Sep 23, 2021, 10:15 AM
•
Updated 939 days ago
Share:
More Stories
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
200ds ago1:25
Pharmacies say they have not received orders for newest COVID booster
204ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
211ds ago0:41
Gov. Hochul: Updated COVID-19 vaccine to be available in NY in the coming days
218ds ago2:13
NYSDOH: COVID numbers up with new variant accounting for 17% of new cases
252ds ago2:30
NYSHD: Hospitalizations caused by COVID increase by 22% in a week
260ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
200ds ago1:25
Pharmacies say they have not received orders for newest COVID booster
204ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
211ds ago0:41
Gov. Hochul: Updated COVID-19 vaccine to be available in NY in the coming days
218ds ago2:13
NYSDOH: COVID numbers up with new variant accounting for 17% of new cases
252ds ago2:30
NYSHD: Hospitalizations caused by COVID increase by 22% in a week
260ds agoAccording to a new study, Remdesivir can significantly
reduce the risk of hospitalization for high-risk COVID-19 patients.
The
antiviral drug was tested on over 500 patients considered high risk due to
either their health conditions or age.
It was found that the drug reduced the risk of
hospitalization by 87% by day 28 and reduced the risk of dying by 81%.
Remdesivir
is currently approved for hospitalized patients 12 and over.
